MAPT and Alzheimer disease: The aims of this study were to (a) evaluate the feasibility of this rapid ‘one pot', multiplexed, targeted proteomic assay to measure biomarkers of interest in clinical cohorts of individuals with AD, other degenerative diseases and healthy controls and (b) explore differences in novel biomarker concentrations between individuals with AD and non-AD classified according to their CSF tau and β-amyloid levels.